For millennia, humans have relied on the ability of plants to produce useful medicines. Recent advances in genetic engineering help us control the natural abilities of plants and transform them into biological factories. The practice is also called ‘pharming’.
See more
See less
Plants have been an alternative production platform for biologics for many years. At Helico, we focus on the development of plant production models for biologics and biosimilars. Using plants to produce therapeutic molecules has many advantages, thanks to their cellular complexity:
• Cost-effective development and production timelines
• Improved manufacturing capabilities
• Low capital expenditure
• Localised production using small green houses
Helico has developed a proprietary computational platform for synthetic biology research and production. With the increasing need for accessible like-saving medicines, our plant models and machine learning algorithms provide the opportunity for biologics production at lower costs and a fraction of the time compared to other host systems. Helico’s computational synthetic biology also provides the tools necessary to produce previously discovered but unproducible drugs using traditional production methods.
Helico creates opportunities to translate therapeutic targets into biologics for commercial use. We have designed BioVerge, a plant-based therapeutics production platform optimised for high yield biologics manufacturing. It comprises SeqOptima, a sequence optimisation technology, and Verdantix, a plant model enhanced for optimal protein production.
– High valued proteins
– Antibodies
Validation of the molecule of interest expressed in plants.
Bioverge applications
